A limited trial examining the effect of RGZ on lung function in comparison with low dose inhaled corticosteroids in steroid naïve smokers with asthma is currently underway in the United Kingdom to determine whether targeting PPARγ may offer therapeutic benefit in the future treatment of asthma and other inflammatory lung diseases. The gene discussed is PPARG; the disease is asthma.